Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 5
Submit an article Journal homepage
1,419
Views
5
CrossRef citations to date
0
Altmetric
Immunotherapeutics – Research Paper

MicroRNA-873-5p suppresses cell malignant behaviors of thyroid cancer via targeting CXCL5 and regulating P53 pathway

Wang ChangDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, Tangshan, Hebei Province, ChinaView further author information
,
Qing ChangDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, Tangshan, Hebei Province, ChinaView further author information
,
Haodong LuDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, Tangshan, Hebei Province, ChinaView further author information
,
Shiguang LiuDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, Tangshan, Hebei Province, ChinaView further author information
,
Yanbing LiDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, Tangshan, Hebei Province, ChinaView further author information
&
Chunyou ChenDepartment of Head and Neck Surgery, Tangshan Gongren Hospital, Tangshan, Hebei Province, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7689-8721View further author information
ORCID Icon
Article: 2065837 | Received 03 Dec 2021, Accepted 11 Apr 2022, Published online: 29 Apr 2022

References

  • Arneth B. Tumor microenvironment. Medicina (Kaunas). 2019;56(1). doi:10.3390/medicina56010015.
  • Zhang W, Wang H, Sun M, Deng X, Wu X, Ma Y, Li M, Shuoa SM, You Q, Miao L, et al. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun (Lond). 2020;40(2–3):69–9. doi:10.1002/cac2.12010.
  • Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2(12):1125–31. doi:10.1158/2326-6066.CIR-14-0160.
  • Zhao J, Ou B, Ham D, Wang P, Zong Y, Zhu C, Liu D, Zheng M, Sun J, Feng H, et al. Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/snail and AKT/GSK3beta/beta-catenin pathways. Mol Cancer. 2017;16(70). doi:10.1186/s12943-017-0629-4.
  • Cui D, Zhao Y, Xu J. Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways. Cancer Biol Ther. 2019;20(5):608–16. doi:10.1080/15384047.2018.1539289.
  • Bai L, Yao N, Qiao G, Wu L, Ma X. CXCL5 contributes to the tumorigenicity of cervical cancer and is post-transcriptionally regulated by miR-577. Int J Clin Exp Pathol. 2020;13:2984–93.
  • Dong G, Zhang R, Xu J, Guo Y. Association between microRNA polymorphisms and papillary thyroid cancer susceptibility. Int J Clin Exp Pathol. 2015;8:13450–57.
  • Han J, Zhang M, Nie C, Jia J, Wang F, Yu J, Bi W, Liu B, Sheng R, He G, et al. miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1. Cell Death Dis. 2019;10(3). doi:10.1038/s41419-019-1444-1.
  • Zhu Y, Zhang X, Qi M, Zhang Y, Ding F. miR-873-5p inhibits the progression of colon cancer via repression of tumor suppressor candidate 3/AKT signaling. J Gastroenterol Hepatol. 2019;34(12):2126–34. doi:10.1111/jgh.14697.
  • Ando Y, Ohuchida K, Otsubo Y, Kibe S, Takesue S, Abe T, Iwamoto C, Shindo K, Moriyama T, Nakata K, et al. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. PLoS One. 2020;15(1):e0228015. doi:10.1371/journal.pone.0228015.
  • Zhang Y, Hu Q, Li G, Li L, Liang S, Zhang Y, Liu J, Fan Z, Li L, Zhou B, et al. ONZIN upregulation by mutant p53 contributes to osteosarcoma metastasis through the CXCL5-MAPK signaling pathway. Cell Physiol Biochem. 2018;48(3):1099–111. doi:10.1159/000491976.
  • Luo M, Hu Z, Kong Y, Li L. MicroRna‑432‑5p inhibits cell migration and invasion by targeting CXCL5 in colorectal cancer. Exp Ther Med. 2021;21(4). doi:10.3892/etm.2021.9732.
  • Wang Z, Liu W, Wang C, Ai Z. miR-873-5p. Inhibits cell migration and invasion of papillary thyroid cancer via regulation of CXCL16. Onco Targets Ther. 2020;13:1037–46. doi:10.2147/OTT.S213168.
  • Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26(2):199–212. doi:10.1038/s41418-018-0246-9.
  • Zhou X, Hao Q, Lu H. Mutant p53 in cancer therapy—the barrier or the path. J Mol Cell Biol. 2019;11(4):293–305. doi:10.1093/jmcb/mjy072.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.